This acquired resistance to PARP inhibitors could be reversed upon restoration of the reading frame of BRCA2 (45), providing a window of opportunity for development of newer and effective strategies for clinical management of BRCA2-mutated cancers. The gene discussed is PARP1; the disease is cancer.